Savient Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: East Brunswick NJ United States (1980)
Status: Acquired by Crealta (2013) → now Amgen

Organization Overview

First Clinical Trial
2003
NCT00286377
First Marketed Drug
2010
pegloticase (krystexxa)
First NDA Approval
2010
pegloticase (krystexxa)
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Savient Pharmaceuticals, Inc.